Rady Children's Hospital - San Diego | Hematology/Oncology Research Center, Peckham Center for Cancer and Blood Disorders

Research site

(Unclaimed)

Location

3020 Childrens Way, MC 5128, San Diego, California, United States of America

Site insights

Top conditions

Top treatments

Cyclophosphamide

Vincristine Sulfate

Etoposide

Carboplatin

Doxorubicin Hydrochloride

Cisplatin

Methotrexate

Vincristine

Cytarabine

Prednisone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 179 total trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lympho...

Active, not recruiting

Leukemia

Drug: Methotrexate

Drug: Thioguanine

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepine...

Active, not recruiting

Prader-Willi Syndrome

Drug: Pitolisant oral tablets

Drug: Placebo oral tablet

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that...

Active, not recruiting

Desmoid Fibromatosis

Unresectable Desmoid Fibromatosis

Drug: Nirogacestat

Procedure: Magnetic Resonance Imaging

Locations recently updated

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)

The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52...

Enrolling

Central Precocious Puberty

Drug: Debio 4326

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)

This is a phase I, multicenter, non-randomized, adaptive, open-label, multiple ascending, intra-participant, dose-escalation study with a long-term e...

Active, not recruiting

Angelman Syndrome

Drug: RO7248824

Allergic Disease Onset Prevention Study (adored)

This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-10...

Active, not recruiting

Atopic Dermatitis

Type 1 Hypersensitivity

Biological: STMC-103H

Biological: Placebo

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant gra...

Enrolling

Recurrent WHO Grade II Glioma

Glioblastoma

Drug: PARP Inhibitor BGB-290

Drug: Temozolomide

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination w...

Enrolling

Solid Tumor

Drug: Cabozantinib

Drug: 13-cis-retinoic acid

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants (ValEAR)

The overall goal of this study is to determine the clinical benefit and safety of antiviral therapy for asymptomatic congenital cytomegalovirus (cCMV...

Active, not recruiting

SNHL

Cmv Congenital

Drug: Valganciclovir

Drug: Simple Syrup

Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. (Aldebaran)

This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion Angelman Syndrome (AS) aged 5-17 years (in...

Enrolling

Angelman Syndrome

Drug: 60 mg QD Alogabat

Drug: 40 mg QD Alogabat

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in childr...

Active, not recruiting

Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas

Drug: Vemurafenib